文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

甲氨蝶呤联合吉非替尼对比甲氨蝶呤单药治疗输卵管异位妊娠的多中心双盲安慰剂对照随机试验(GEM3):试验方案

A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol.
PubMed 文献 · Trials · 2018-11-20

本研究为多中心、双盲、安慰剂对照随机试验,计划在英国约70个中心招募328例预处理血清hCG为1000-5000 IU/L的输卵管异位妊娠女性,按1:1随机接受单次肌注甲氨蝶呤(50 mg/m2)联合口服吉非替尼(250 mg)或安慰剂每日7天,主要结局为需要手术干预的比例。

要点

  • 针对hCG 1000-5000 IU/L的输卵管异位妊娠,评估吉非替尼联合甲氨蝶呤能否减少手术需求。
  • 给药方案:单次肌注甲氨蝶呤50 mg/m2,联合口服吉非替尼250 mg或安慰剂每日7天。
  • 主要结局为输卵管异位妊娠需手术干预;次要结局包括需再次甲氨蝶呤、hCG≤15 IU/L的消退时间等。

核心结论

  • 该试验旨在评估吉非替尼联合甲氨蝶呤对比甲氨蝶呤单药能否减少输卵管异位妊娠的手术干预需求。
  • 若有效,研究者认为吉非替尼联合甲氨蝶呤可能成为稳定输卵管异位妊娠的标准治疗。

研究设计与样本

  • 多中心、双盲、安慰剂对照、随机试验,计划在英国约70个中心开展。
  • 计划招募328例输卵管异位妊娠女性,预处理血清hCG为1000-5000 IU/L。
  • 按1:1比例通过安全在线系统随机分配。

主要发现

  • 早期试验中,吉非替尼联合甲氨蝶呤在超过70%的病例中使输卵管异位妊娠消退而无需手术,未引起显著毒性且耐受良好。
  • 临床前研究发现输卵管异位妊娠着床部位表达高水平表皮生长因子受体。

关键数值与推荐

  • 干预组:单次肌注甲氨蝶呤50 mg/m2联合口服吉非替尼250 mg每日7天;对照组:甲氨蝶呤联合匹配安慰剂。
  • 主要结局:输卵管异位妊娠需要手术干预。
  • 次要结局包括需要进一步甲氨蝶呤治疗、输卵管异位妊娠消退时间(血清hCG≤15 IU/L)、治疗相关医院就诊次数及消退后3个月内月经恢复。

临床怎么用

  • 对于预处理血清hCG为1000-5000 IU/L的稳定输卵管异位妊娠女性,该试验探索吉非替尼联合甲氨蝶呤能否减少手术并加速消退。
  • 参与者与医疗提供者在整个试验期间对治疗分配保持盲态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. Treatment options include surgery and medical management. Stable women with tEPs with pre-treatment serum human chorionic gonadotrophin (hCG) levels < 1000 IU/L respond well to outpatient medical treatment with intramuscular methotrexate. However, tEPs with hCG > 1000 IU/L can take significant time to resolve with methotrexate and require multiple outpatient monitoring visits. In pre-clinical studies, we found that tEP implantation sites express high levels of epidermal growth factor receptor. In early-phase trials, we found that combination therapy with gefitinib, an orally active epidermal growth factor receptor antagonist, and methotrexate resolved tEPs without the need for surgery in over 70% of cases, did not cause significant toxicities, and was well tolerated. We describe the protocol of a randomised trial to assess the efficacy of combination gefitinib and methotrexate, versus methotrexate alone, in reducing the need for surgical intervention for tEPs. METHODS AND ANALYSIS: We propose to undertake a multi-centre, double-blind, placebo-controlled, randomised trial (around 70 sites across the UK) and recruit 328 women with tEPs (with pre-treatment serum hCG of 1000-5000 IU/L). Women will be randomised in a 1:1 ratio by a secure online system to receive a single dose of intramuscular methotrexate (50 mg/m2) and either oral gefitinib or matched placebo (250 mg) daily for 7 days. Participants and healthcare providers will remain blinded to treatment allocation throughout the trial. The primary outcome is the need for surgical intervention for tEP. Secondary outcomes are the need for further methotrexate treatment, time to resolution of the tEP (serum hCG ≤ 15 IU/L), number of hospital visits associated with treatment (until resolution or scheduled/emergency surgery), and the return of menses by 3 months after resolution. We will also assess adverse events and reactions until day of resolution or surgery, and participant-reported acceptability at 3 months. DISCUSSION: A medical intervention that reduces the need for surgery and resolves tEP faster would be a favourable treatment alternative. If effective, we believe that gefitinib and methotrexate could become standard care for stable tEPs. TRIAL REGISTRATION: ISRCTN Registry ISRCTN67795930 . Registered 15 September 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. May J, Duncan C, Mol B, et al. A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol. Trials. 2018. PMID: 30458863. doi:10.1186/s13063-018-3008-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。